A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis
Psoriasis Treatment Center of Central New Jersey
Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Eligibility
- Age range
- 18–64 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Male or female adult 18-64 years of age at time of screening. 2. Diagnosis of prurigo nodularis for ≥ 3 months. 3. Moderate-to-Severe prurigo nodularis as determined by at least 10 PN lesions on legs and/or arms and/or trunk at screening and baseline . 4. Failure of at least a 2-week course of medium to super potent TCS or TCS is not medically advisable for subject. 5. Females of childbearing potential must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing. Note:…
Interventions
- DrugUpadacitinib
All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
Location
- Eczema Treatment Center of New JerseyEast Windsor, New Jersey